Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC us...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuki Zaizen, Masahito Nakano, Kazuta Fukumori, Yoichi Yano, Kota Takaki, Takashi Niizeki, Kotaro Kuwaki, Masaru Fukahori, Takahiko Sakaue, Sohei Yoshimura, Mika Nakazaki, Ryoko Kuromatsu, Shusuke Okamura, Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hironori Koga, Takuji Torimura
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	hepatocellular carcinoma hepatic arterial infusion chemotherapy cisplatin sorafenib multikinase inhibitor risk factors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8ae148b8cb474f8ead8158db1e124ed8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8ae148b8cb474f8ead8158db1e124ed8
record_format	dspace
spelling	oai:doaj.org-article:8ae148b8cb474f8ead8158db1e124ed82021-11-11T15:27:18ZHepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis10.3390/cancers132152822072-6694https://doaj.org/article/8ae148b8cb474f8ead8158db1e124ed82021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5282https://doaj.org/toc/2072-6694Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC using propensity score-matched analysis. We enrolled 331 patients with intrahepatic advanced HCC who received HAIC with cisplatin (n = 88) or sorafenib (n = 243) between June 2006 and March 2020. No significant difference was observed in OS between HAIC with cisplatin and sorafenib cohorts (median survival time [MST]: 14.0 vs. 12.3 months; <i>p</i> = 0.0721). To reduce confounding effects, 166 patients were selected using propensity score-matched analysis (n = 83 for each treatment). HAIC with cisplatin significantly prolonged OS compared with sorafenib (MST: 15.6 vs. 11.0 months; <i>p</i> = 0.0157). Following stratification according to the Child-Pugh classification, for patients with class A (MST: 24.0 vs. 15.0 months; <i>p</i> = 0.0145), HAIC with cisplatin rather than sorafenib significantly prolonged OS. Our findings suggest that HAIC with cisplatin demonstrates longer prognostic effects than sorafenib in intrahepatic advanced HCC.Yuki ZaizenMasahito NakanoKazuta FukumoriYoichi YanoKota TakakiTakashi NiizekiKotaro KuwakiMasaru FukahoriTakahiko SakaueSohei YoshimuraMika NakazakiRyoko KuromatsuShusuke OkamuraHideki IwamotoShigeo ShimoseTomotake ShironoYu NodaNaoki KamachiHironori KogaTakuji TorimuraMDPI AGarticlehepatocellular carcinomahepatic arterial infusion chemotherapycisplatinsorafenibmultikinase inhibitorrisk factorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5282, p 5282 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatocellular carcinoma hepatic arterial infusion chemotherapy cisplatin sorafenib multikinase inhibitor risk factors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	hepatocellular carcinoma hepatic arterial infusion chemotherapy cisplatin sorafenib multikinase inhibitor risk factors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yuki Zaizen Masahito Nakano Kazuta Fukumori Yoichi Yano Kota Takaki Takashi Niizeki Kotaro Kuwaki Masaru Fukahori Takahiko Sakaue Sohei Yoshimura Mika Nakazaki Ryoko Kuromatsu Shusuke Okamura Hideki Iwamoto Shigeo Shimose Tomotake Shirono Yu Noda Naoki Kamachi Hironori Koga Takuji Torimura Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
description	Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC using propensity score-matched analysis. We enrolled 331 patients with intrahepatic advanced HCC who received HAIC with cisplatin (n = 88) or sorafenib (n = 243) between June 2006 and March 2020. No significant difference was observed in OS between HAIC with cisplatin and sorafenib cohorts (median survival time [MST]: 14.0 vs. 12.3 months; <i>p</i> = 0.0721). To reduce confounding effects, 166 patients were selected using propensity score-matched analysis (n = 83 for each treatment). HAIC with cisplatin significantly prolonged OS compared with sorafenib (MST: 15.6 vs. 11.0 months; <i>p</i> = 0.0157). Following stratification according to the Child-Pugh classification, for patients with class A (MST: 24.0 vs. 15.0 months; <i>p</i> = 0.0145), HAIC with cisplatin rather than sorafenib significantly prolonged OS. Our findings suggest that HAIC with cisplatin demonstrates longer prognostic effects than sorafenib in intrahepatic advanced HCC.
format	article
author	Yuki Zaizen Masahito Nakano Kazuta Fukumori Yoichi Yano Kota Takaki Takashi Niizeki Kotaro Kuwaki Masaru Fukahori Takahiko Sakaue Sohei Yoshimura Mika Nakazaki Ryoko Kuromatsu Shusuke Okamura Hideki Iwamoto Shigeo Shimose Tomotake Shirono Yu Noda Naoki Kamachi Hironori Koga Takuji Torimura
author_facet	Yuki Zaizen Masahito Nakano Kazuta Fukumori Yoichi Yano Kota Takaki Takashi Niizeki Kotaro Kuwaki Masaru Fukahori Takahiko Sakaue Sohei Yoshimura Mika Nakazaki Ryoko Kuromatsu Shusuke Okamura Hideki Iwamoto Shigeo Shimose Tomotake Shirono Yu Noda Naoki Kamachi Hironori Koga Takuji Torimura
author_sort	Yuki Zaizen
title	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
title_short	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
title_full	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
title_fullStr	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
title_full_unstemmed	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
title_sort	hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for intrahepatic advanced hepatocellular carcinoma: a propensity score-matched analysis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/8ae148b8cb474f8ead8158db1e124ed8
work_keys_str_mv	AT yukizaizen hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT masahitonakano hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT kazutafukumori hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT yoichiyano hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT kotatakaki hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT takashiniizeki hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT kotarokuwaki hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT masarufukahori hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT takahikosakaue hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT soheiyoshimura hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT mikanakazaki hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT ryokokuromatsu hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT shusukeokamura hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT hidekiiwamoto hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT shigeoshimose hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT tomotakeshirono hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT yunoda hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT naokikamachi hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT hironorikoga hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT takujitorimura hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis
_version_	1718435251511885824

Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

Ejemplares similares